Rienso: new parenteral iron therapy for anaemia in CKD

Rienso (ferumoxytol) is an injectable colloidal iron-carbohydrate complex for the treatment of iron deficiency anaemia in chronic kidney disease (CKD).

Dosage of Rienso is based on body weight and pre-treatment haemoglobin levels | SCIENCE PHOTO LIBRARY
Dosage of Rienso is based on body weight and pre-treatment haemoglobin levels | SCIENCE PHOTO LIBRARY


Ferumoxytol is a parenteral colloidal iron-carbohydrate complex.1 A carbohydrate shell isolates the bioactive iron to minimise its immunogenicity, which may allow administration of higher doses than other intravenous iron preparations.1,2


The safety and efficacy of intravenous ferumoxytol were assessed in three open-label studies involving 837 patients with CKD and iron-deficiency anaemia. Patients were randomised to receive either ferumoxytol (two 510mg injections 2–8 days apart) or oral iron (200mg elemental iron daily for 21 days). Patients in studies 1 and 2 were not receiving haemodialysis while those in the third study were.1

Haemoglobin increase

In the first study (n=304), ferumoxytol was associated with a significant increase in haemoglobin at day 35 (the primary efficacy endpoint) compared with oral iron (mean increase 0.82g/dL versus 0.16g/dL; (p<0.0001). In addition, more than twice as many ferumoxytol patients achieved a ≥1g/dL increase in haemoglobin at day 35 (39% versus 18.4% of placebo patients). Similar findings were reported in the other two studies.1–3

Well tolerated

Ferumoxytol was well tolerated in all three studies.1–3 In a double-blind cross-over safety study involving 750 anaemic patients with CKD stages 1–5 and 5D, ferumoxytol was well tolerated in all stages of CKD with similar rates of adverse events to placebo.4


  1. Rienso Summary of Product Characteristics, June 2012
  2. Provenzano R et al. Clin J Am Soc Nephrol 2009; 4: 386-93.
  3. Spinowitz BS et al. J Am Soc Nephrol 2008; 19: 1599-1605.
  4. Singh A et al. Am J Kidney Dis 2008; 52: 907-15.

View Rienso drug record
Further information: Takeda

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman leans on a desk holding her stomach in pain.

Draft NICE approval for new fibroid treatment

Around 4500 women in England and Wales will be eligible...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...